NEWS - Approval of Actemra (tocilizumab) delayed further

[Guest guest]

Roche hit as FDA seeks more data on arthritis drug

By Reid

ZURICH, Dec 4 (Reuters) - U.S. approval for Roche Holding AG's

(ROG.VX: Quote, Profile, Research, Stock Buzz) Actemra has been

delayed further after regulators asked for more non-clinical data on

the potential blockbuster rheumatoid arthritis drug.

The Swiss group said on Thursday the Food and Drug Administration

(FDA) had requested additional animal model data but had not ordered

further clinical studies, and that the company would submit the

required information in the third quarter of next year.

*****************************************************

Read the entire article here:

http://www.reuters.com/article/euIpoNews/idUSL446342220081204

Not an MD